These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27612501)

  • 41. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.
    Schievink B; Kröpelin T; Mulder S; Parving HH; Remuzzi G; Dwyer J; Vemer P; de Zeeuw D; Lambers Heerspink HJ
    Diabetes Obes Metab; 2016 Jan; 18(1):64-71. PubMed ID: 26434564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians.
    Pavkov ME; Bennett PH; Knowler WC; Krakoff J; Sievers ML; Nelson RG
    JAMA; 2006 Jul; 296(4):421-6. PubMed ID: 16868300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.
    Presta P; Minutolo R; Iodice C; Comi N; Casoria V; Fuiano L; Caglioti C; Conte G; Fuiano G
    Eur J Intern Med; 2011 Dec; 22(6):e90-4. PubMed ID: 22075320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.
    Wheelock KM; Cai J; Looker HC; Merchant ML; Nelson RG; Fufaa GD; Weil EJ; Feldman HI; Vasan RS; Kimmel PL; Rovin BH; Mauer M; Klein JB;
    PLoS One; 2017; 12(7):e0180964. PubMed ID: 28700653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R; Faraone R; Ruggenent P; Remuzzi G
    J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.
    Afshinnia F; Nair V; Lin J; Rajendiran TM; Soni T; Byun J; Sharma K; Fort PE; Gardner TW; Looker HC; Nelson RG; Brosius FC; Feldman EL; Michailidis G; Kretzler M; Pennathur S
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31573977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
    Guo LL; Pan Y; Jin HM
    Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
    Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of losartan on the recoverability of renal function in anuric and oliguric patients with a solitary obstructed kidney: a double-blind randomized placebo-controlled trial.
    Elkappany S; Hashem A; Elkarta A; Sheashaa H; Osman Y; Shokeir AA
    BJU Int; 2020 Dec; 126(6):715-721. PubMed ID: 32648662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes.
    Montanari A; Pelà G; Musiari L; Crocamo A; Boeti L; Cabassi A; Biggi A; Cherney DZ
    Am J Physiol Renal Physiol; 2013 Jul; 305(1):F42-51. PubMed ID: 23657857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort.
    Saulnier PJ; Gand E; Velho G; Mohammedi K; Zaoui P; Fraty M; Halimi JM; Roussel R; Ragot S; Hadjadj S;
    Diabetes Care; 2017 Mar; 40(3):367-374. PubMed ID: 27998909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of achieved systolic blood pressure on renal function in hypertensive patients.
    Okin PM; Kjeldsen SE; Devereux RB
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):271-276. PubMed ID: 29474712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
    Liou HH; Huang TP; Campese VM
    Nephron; 1995; 69(1):41-8. PubMed ID: 7891796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
    Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
    Waanders F; Vaidya VS; van Goor H; Leuvenink H; Damman K; Hamming I; Bonventre JV; Vogt L; Navis G
    Am J Kidney Dis; 2009 Jan; 53(1):16-25. PubMed ID: 18823687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.